Pei Shu

Pei Shu (裴樞) (841-July 5, 905), courtesy name Jisheng (紀聖) or Huasheng (化聖), was an official of the Chinese Tang dynasty, who served two terms as chancellor during the reigns of Emperor Zhaozong and Emperor Zhaozong's son Emperor Ai, near the end of the dynasty. He was killed in a purge of high-level Tang officials by the warlord Zhu Quanzhong the military governor (''Jiedushi'') of Xuanwu Circuit (宣武, headquartered in modern Kaifeng, Henan), who was then preparing to seize the throne. Provided by Wikipedia
Showing 1 - 10 results of 10 for search 'Pei Shu', query time: 0.03s Refine Results
  1. 1
    Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor

    Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor by Pei Shu, Pei Shu, Fang Wang, Fang Wang, Xin Wang, Xin Wang

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers

    Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers by Can Jiang, Pei Shu, Kexun Zhou

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    DMS Algorithm in the Application of the Map/Reduce Tasks Schedule

    DMS Algorithm in the Application of the Map/Reduce Tasks Schedule by PEI Shu-jun, KONG De-kai, MIAO Hui

    Published 2019-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Targeted therapy acts to sensitize stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer

    Targeted therapy acts to sensitize stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer by Xiye Sun, Pei Shu, Pei Shu, Yali Shen, Zhiping Li, Ning Liu, Ganlu Ouyang, Yuanling Tang, Meijuan Huang, Xin Wang

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Risk factors of hyperuricemia in patients with non-dialytic chronic kidney disease

    Risk factors of hyperuricemia in patients with non-dialytic chronic kidney disease by Li Pei-shu, Wu Rui-xia, Tan Zhi-cheng

    Published 2021-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor

    Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells agains... by Weiting Liao, Ge Gao, Xia He, Pei Shu, Qizhi Ma, Benxia Zhang, Diyuan Qin, Yongsheng Wang

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Ectopic repression of receptor tyrosine kinase–like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial–mesenchymal transition

    Ectopic repression of receptor tyrosine kinase–like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial–mesenchymal transition by Ying Xu, Yan-Hui Ma, Ying-Xin Pang, Zhe Zhao, Jing-Jing Lu, Hong-Luan Mao, Pei-Shu Liu

    Published 2017-04-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Preclinical Development and Phase I Study of ZSYY001, a Polymeric Micellar Paclitaxel for Advanced Solid Tumor

    Preclinical Development and Phase I Study of ZSYY001, a Polymeric Micellar Paclitaxel for Advanced Solid Tumor by Ge Gao, Pei Shu, Youzhen Tan, Tongsen Zheng, Wenmao Fan, Luding Lu, Huan Zhou, Zishu Wang, Ling Liu, Zhiqiang Liu, Yongsheng Wang

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors

    Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors by Pei Shu, Xiaoyu Li, Qi Zhou, Guiling Li, Keqiang Zhang, Li Yuan, Yixian Liu, Qiu Li, Yongsheng Wang, Hui Xie, Li Zheng

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Epidemiologic investigation on neurological complications following neuraxial anesthesia in 2.7 million cases in Southwest China

    Epidemiologic investigation on neurological complications following neuraxial anesthesia in 2.7 million cases in Southwest China by Li-pei Shu, Jie-mei Ji, Zhong-xuan Mao, Xiang-li Xiao, Jian Lai, Yu Dai, Shan-shan Wei, Kai-yuan Liang, Yang Zhao, Ya-jun He, Yu-nan Lin, Jing-chen Liu

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: